Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Wall Street Analysts Think Samsara Inc. (IOT) Could Surge 28.21%: Read This Before Placing a Bet
Wall Street Analysts Think Samsara Inc. (IOT) Could Surge 28.21%: Read This Before Placing a Bet

Samsara Inc. (IOT) closed the last trading session at $34.06, gaining 17.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Wall Street Analysts Believe Signet (SIG) Could Rally 32.71%: Here's is How to Trade
Wall Street Analysts Believe Signet (SIG) Could Rally 32.71%: Here's is How to Trade

Signet (SIG) closed the last trading session at $84.56, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Optical Cable Corporation: Strong Earnings, But Hurdles Remain
Optical Cable Corporation: Strong Earnings, But Hurdles Remain

Key Points

FuelCell Energy Just Got a Wake-Up Call From Wall Street
FuelCell Energy Just Got a Wake-Up Call From Wall Street

Key Points

Huntington's Texas Deals to Drive Higher Profitability Through 2028
Huntington's Texas Deals to Drive Higher Profitability Through 2028

Huntington Bancshares Incorporated’s HBAN strategic expansion in Texas is gaining momentum, supported by targeted acquisitions, geographic diversification and deeper penetration into high-growth

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics, Inc. (ORKA) closed the last trading session at $66.93, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets

Does Loar Holdings Inc. (LOAR) Have the Potential to Rally 29.16% as Wall Street Analysts Expect?
Does Loar Holdings Inc. (LOAR) Have the Potential to Rally 29.16% as Wall Street Analysts Expect?

Loar Holdings Inc. (LOAR) closed the last trading session at $65.5, gaining 7.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

Wall Street Analysts See a 26.04% Upside in Carnival (CCL): Can the Stock Really Move This High?
Wall Street Analysts See a 26.04% Upside in Carnival (CCL): Can the Stock Really Move This High?

Carnival (CCL) closed the last trading session at $27.73, gaining 11.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts Believe Dell Technologies (DELL) Could Rally 27.29%: Here's is How to Trade
Wall Street Analysts Believe Dell Technologies (DELL) Could Rally 27.29%: Here's is How to Trade

Dell Technologies (DELL) closed the last trading session at $381.78, gaining 59.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

Wall Street Analysts See a 28.17% Upside in Cushman & Wakefield (CWK): Can the Stock Really Move This High?
Wall Street Analysts See a 28.17% Upside in Cushman & Wakefield (CWK): Can the Stock Really Move This High?

Cushman & Wakefield (CWK) closed the last trading session at $13.81, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by

WFC Stock Rises as CFO Sees Stronger Q2 NII, Reaffirms $50B 2026 Target
WFC Stock Rises as CFO Sees Stronger Q2 NII, Reaffirms $50B 2026 Target

Shares of Wells Fargo & Company WFC rose nearly 1.3% after its chief financial officer (CFO), Mike Santomassimo, expressed confidence in the company’s net interest income (NII) outlook at the Morgan

ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push

ANI Pharmaceuticals ANIP is leaning harder into its Rare Disease franchise as growth increasingly concentrates around Purified Cortrophin Gel. The next step is a sharper commercial push into acute

Techtarget

WKN: A0MRMK / Symbol: TTGT / Name: TechTarget / Stock / Software & IT Services / Small Cap /

€30.00
-0.660%

Techtarget Inc.

WKN: A40MZE / Name: Techtarget Inc. / Stock / ? /

€3.22
1.900%